Compare · ELV vs LH
ELV vs LH
Side-by-side comparison of Elevance Health Inc. (ELV) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $80.93B, about 3.8x LH ($21.03B).
- LH has been more active in the news (9 items in the past 4 weeks vs 8 for ELV).
- LH has more recent analyst coverage (25 ratings vs 22 for ELV).
- Company
- Elevance Health Inc.
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $80.93B
- $21.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 9
- Recent ratings
- 22
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest ELV
- Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
- Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
- Elevance Health upgraded by BofA Securities with a new price target
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
- Evercore ISI initiated coverage on Elevance Health with a new price target
- SEC Form PX14A6G filed by Elevance Health Inc.
- Elevance Health Announces Leadership Appointments to Strengthen Execution and Drive Growth
- Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2026 Results on April 22, 2026
Latest LH
- Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits